tiprankstipranks
Trending News
More News >

Acura Pharmaceuticals Extends Promissory Note Maturity Date

Story Highlights
  • Acura Pharmaceuticals’ $6.0 million note was converted into shares by AD Pharma.
  • AD Pharma now owns about 65% of Acura’s stock, with a note maturity extension to December 2025.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Acura Pharmaceuticals Extends Promissory Note Maturity Date

Don’t Miss TipRanks’ Half-Year Sale

Acura Pharmaceuticals ( (ACUR) ) has issued an announcement.

On June 28, 2019, Acura Pharmaceuticals entered into a $6.0 million promissory note with John Schutte, which was later transferred to AD Pharma. By June 9, 2021, AD Pharma converted the note and accrued interest into 42,984,375 shares of Acura’s common stock. As of May 29, 2025, AD Pharma owns approximately 65% of Acura’s outstanding common stock, excluding a warrant for 10 million shares. The maturity date of a secured promissory note was extended to December 31, 2025, reflecting strategic financial adjustments.

More about Acura Pharmaceuticals

Average Trading Volume: 8,025

Technical Sentiment Signal: Sell

Current Market Cap: $1.32M

For detailed information about ACUR stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1